JP2010518816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518816A5 JP2010518816A5 JP2009549472A JP2009549472A JP2010518816A5 JP 2010518816 A5 JP2010518816 A5 JP 2010518816A5 JP 2009549472 A JP2009549472 A JP 2009549472A JP 2009549472 A JP2009549472 A JP 2009549472A JP 2010518816 A5 JP2010518816 A5 JP 2010518816A5
- Authority
- JP
- Japan
- Prior art keywords
- herpes simplex
- simplex virus
- nucleic acid
- polypeptide
- ing4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 claims description 26
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 241000700584 Simplexvirus Species 0.000 claims 27
- 150000007523 nucleic acids Chemical group 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 101150076998 ICP34.5 gene Proteins 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 231100000501 nonneurotoxic Toxicity 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 3
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims 2
- 101150027249 RL1 gene Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000044392 human ING4 Human genes 0.000 description 2
- -1 BC007781 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 101100233089 Mus musculus Ing4 gene Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0703066A GB0703066D0 (en) | 2007-02-16 | 2007-02-16 | Viruses |
| GB0703066.1 | 2007-02-16 | ||
| US91686207P | 2007-05-09 | 2007-05-09 | |
| US60/916,862 | 2007-05-09 | ||
| PCT/GB2008/000527 WO2008099189A2 (en) | 2007-02-16 | 2008-02-15 | Herpes simplex viruses and methods of viral replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518816A JP2010518816A (ja) | 2010-06-03 |
| JP2010518816A5 true JP2010518816A5 (enExample) | 2011-04-07 |
| JP5442452B2 JP5442452B2 (ja) | 2014-03-12 |
Family
ID=39271813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549472A Expired - Fee Related JP5442452B2 (ja) | 2007-02-16 | 2008-02-15 | 単純ヘルペスウイルスおよびウイルス複製法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8163292B2 (enExample) |
| EP (1) | EP2114420B1 (enExample) |
| JP (1) | JP5442452B2 (enExample) |
| GB (1) | GB2446721B (enExample) |
| WO (1) | WO2008099189A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| EP2114420B1 (en) * | 2007-02-16 | 2016-01-27 | Virttu Biologics Limited | Herpes simplex viruses and methods of viral replication |
| US8859256B2 (en) | 2011-10-05 | 2014-10-14 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
| EP2662117A1 (en) * | 2012-05-11 | 2013-11-13 | Virttu Biologics Limited | Herpes Simplex Virus for the treatment of liver cancer |
| US20140140959A1 (en) | 2012-10-05 | 2014-05-22 | Aladar A. Szalay | Energy Absorbing-Based Diagnostic and Therapeutic Methods Employing Nucleic Acid Molecules Encoding Chromophore-Producing Enzymes |
| US10238700B2 (en) | 2014-01-02 | 2019-03-26 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| KR102122463B1 (ko) | 2014-10-14 | 2020-06-15 | 할로자임, 아이엔씨 | 아데노신 디아미네이즈-2(ada2)의 조성물, 이의 변이체 및 이를 사용하는 방법 |
| IL310729A (en) | 2016-04-15 | 2024-04-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2017181148A2 (en) | 2016-04-15 | 2017-10-19 | Alpine Immune Sciences, Inc. | Icos ligand variant immunomodulatory proteins and uses thereof |
| US11834490B2 (en) | 2016-07-28 | 2023-12-05 | Alpine Immune Sciences, Inc. | CD112 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| EP3580341A4 (en) | 2017-02-09 | 2020-11-04 | Indapta Therapeutics, Inc. | Engineered natural killer (nk) cells and compositions and methods thereof |
| IL268781B2 (en) | 2017-03-16 | 2025-09-01 | Alpine Immune Sciences Inc | Cd80 variant immunomodulatory proteins and uses thereof |
| WO2018170021A1 (en) | 2017-03-16 | 2018-09-20 | Alpine Immune Sciences, Inc. | Pd-l1 variant immunomodulatory proteins and uses thereof |
| US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| EA202090974A1 (ru) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | Вариантные иммуномодулирующие белки лиганда icos и сопутствующие композиции и способы |
| WO2019136179A1 (en) | 2018-01-03 | 2019-07-11 | Alpine Immune Sciences, Inc. | Multi-domain immunomodulatory proteins and methods of use thereof |
| CA3177467A1 (en) | 2018-06-04 | 2019-12-12 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| US11505782B2 (en) | 2018-06-04 | 2022-11-22 | Calidi Biotherapeutics, Inc. | Cell-based vehicles for potentiation of viral therapy |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| EP3844276A2 (en) | 2018-08-28 | 2021-07-07 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7329593B2 (ja) | 2018-11-06 | 2023-08-18 | カリディ・バイオセラピューティクス・インコーポレイテッド | 細胞媒介性腫瘍溶解性ウイルス治療のための増強された系 |
| CN113891934A (zh) | 2018-11-21 | 2022-01-04 | 因达普塔治疗公司 | 扩增天然杀伤（nk）细胞子集的方法以及相关组合物和方法 |
| CA3120868A1 (en) | 2018-11-30 | 2020-06-04 | Alpine Immune Sciences, Inc. | Cd86 variant immunomodulatory proteins and uses thereof |
| CA3176660A1 (en) | 2019-02-27 | 2020-09-03 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| US12024709B2 (en) | 2019-02-27 | 2024-07-02 | Actym Therapeutics, Inc. | Immunostimulatory bacteria engineered to colonize tumors, tumor-resident immune cells, and the tumor microenvironment |
| CA3149164A1 (en) * | 2019-09-03 | 2021-03-11 | Suma Krishnan | Compositions and methods for the treatment of congenital ichthyoses |
| EP4139439A1 (en) | 2020-04-22 | 2023-03-01 | Indapta Therapeutics, Inc. | Natural killer (nk) cell compositions and methods for generating same |
| TW202241479A (zh) | 2020-12-30 | 2022-11-01 | 美商安迅生物製藥公司 | 遞送外來抗原之溶瘤病毒及表現靶向外來抗原之嵌合受體之經工程化免疫細胞之組合療法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000023589A2 (en) | 1998-10-20 | 2000-04-27 | Incyte Pharmaceuticals, Inc. | Proliferation and apoptosis related proteins |
| CN1183250C (zh) * | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| GB0326798D0 (en) | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| JP2007511216A (ja) * | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| CN1714871A (zh) | 2004-06-29 | 2006-01-04 | 上海人类基因组研究中心 | 人类ing4基因作为化疗药物增敏剂的用途 |
| EP2114420B1 (en) * | 2007-02-16 | 2016-01-27 | Virttu Biologics Limited | Herpes simplex viruses and methods of viral replication |
| CN101058809B (zh) | 2007-04-02 | 2010-09-08 | 苏州大学 | 人源化改造的鼠ing4基因及其腺病毒表达载体在制备治疗肺癌的药物中的应用 |
-
2008
- 2008-02-15 EP EP08709418.1A patent/EP2114420B1/en not_active Not-in-force
- 2008-02-15 JP JP2009549472A patent/JP5442452B2/ja not_active Expired - Fee Related
- 2008-02-15 GB GB0802868A patent/GB2446721B/en not_active Expired - Fee Related
- 2008-02-15 WO PCT/GB2008/000527 patent/WO2008099189A2/en not_active Ceased
- 2008-02-15 US US12/527,380 patent/US8163292B2/en not_active Expired - Fee Related
-
2012
- 2012-03-12 US US13/417,708 patent/US8969063B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010518816A5 (enExample) | ||
| Porro et al. | The regulatory role of IL-10 in neurodegenerative diseases | |
| Donegan et al. | A novel role for brain interleukin-6: facilitation of cognitive flexibility in rat orbitofrontal cortex | |
| JP2020515572A (ja) | 横隔膜特異的核酸調節エレメントならびにその方法および使用 | |
| CN104039833A (zh) | 针对hpv的疫苗 | |
| Steinman et al. | Experimental encephalomyelitis at age 90, still relevant and elucidating how viruses trigger disease | |
| Mandel et al. | Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production | |
| WO2017132332A1 (en) | Chimeric hepatitis d virus antigen and hepatitis b virus pre s1 genes for use alone or in vaccines contaning hepatitis b virus genes | |
| Zhao et al. | The regulation of antiviral activity of interferon epsilon | |
| WO2019135879A1 (en) | Modified macrophages and macrophage precursors and associated methods | |
| Zhang et al. | Suppressor of cytokine signaling 3 inhibits head kidney macrophage activation and cytokine expression in Scophthalmus maximus | |
| Xu et al. | The gene and virus-induced expression of IRF-5 in grass carp Ctenopharyngodon idella | |
| Xiang et al. | Characteristics of the interferon regulatory factor pairs zfIRF5/7 and their stimulation expression by ISKNV Infection in zebrafish (Danio rerio) | |
| CN102180961B (zh) | 黑青斑河鲀干扰素IFNγ2及其制备方法和应用 | |
| JP2007504840A5 (enExample) | ||
| Cheng et al. | Cloning, expression and functional analysis of the duck Toll-like receptor 5 (TLR5) gene | |
| Liang et al. | Negative regulation of interferon regulatory factor 6 (IRF6) in interferon and NF-κB signalling pathways of common carp (Cyprinus carpio L.) | |
| Santos et al. | Teleostean IL11b exhibits complementing function to IL11a and expansive involvement in antibacterial and antiviral responses | |
| JP2016508036A (ja) | Ｂｐｉｆｂ４タンパク質の変異体 | |
| Pedras-Vasconcelos et al. | Immunotherapy with CpG oligonucleotides and antibodies to TNF-α rescues neonatal mice from lethal arenavirus-induced meningoencephalitis | |
| US20240076665A1 (en) | Regulatory elements for schwann cell-specific gene expression | |
| Li et al. | Cloning, analysis, and anti–duck Tembusu virus innate immune response of Cherry Valley duck tripartite motif-containing 32 | |
| CN109847054B (zh) | TgGRA15在制备诱导I型干扰素的药物中的应用 | |
| JPWO2014157595A1 (ja) | 新規なポリペプチドおよびその利用 | |
| CN101041818A (zh) | 重组生产胰高血糖素样肽－2的方法 |